Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia

European Journal of Haematology

Volumn 84, Issue 3, 2010, Pages 271-273

  Torres, Antonio ^a   Serrano, Josefina ^a   Rojas, Rafael ^a   Martín, Vanesa ^a   Martín, Carmen ^a   Tabares, Salvador ^a   Molina, José R ^a   Capote, Manuel ^a   Martínez, Francisco ^a   Gómez, Pedro ^a   Sánchez García, Joaquín ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUSARIOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LETTER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NOSE INFECTION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDIES; PYRIMIDINES; TRANSPLANTATION CONDITIONING; TRIAZOLES; YOUNG ADULT;

EID: 76249128351     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01367.x     Document Type: Letter

References (9)

1. Leather HL, Wingard JR. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with haematological malignancies. Blood Rev 2006 20 : 267 287.
2. Bow EJ. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 2008 140 : 133 152.
3. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003 101 : 3365 3372.
4. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005 131 : 22 8.
5. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of Aspergillosis: clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 360.
6. Vehreschild JJ, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007 55 : 445 449.
7. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallmen M, Pi J, Metha J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007 40 : 451 456.
8. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, Diekema DJ. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006 55 : 209 212.
9. Wingard JR, Carter SL, Walsh J, et al. The Blood and Marrow Transplant Clinical Trials Network. Results of a Randomized, double-blind trial of fluconazole (FLU) vs. Voriconazole (VORI) for the prevention of invasive fungal infection (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007 106 : 5349.